P418: Dose escalation of oral 5-aminosalicylic acid for ulcerative colitis with Mayo endoscopic subscore of one improves long-term prognosis: a one-year multicentre, open-label, randomized controlled trial.ECCO’23 CopenhagenYear: 2023
Authors: Aoki, Y.(1)*;Fukuda, T.(1,2,3);Kiyohara, H.(1,2);Yokoyama, A.(4);Nakazawa, A.(4);Yoshimatsu, Y.(1);Sugimoto, S.(1);Nanki, K.(1);Mikami, Y.(1);Fukuhara, K.(5);Mizuno, S.(1);Sujino, T.(6);Mutaguchi, M.(6);Takabayashi, K.(6);Morohoshi, Y.(3);Hosoda, Y.(7);Ogata, H.(6);Iwao, Y.(5);Naganuma, M.(1,8);Kanai, T.(1);
(1)Keio University School of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Tokyo, Japan;(2)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(3)Yokohama Municipal Citizen's Hospital, Department of Gastroenterology, Yokohama, Japan;(4)Tokyo Saiseikai Central Hospital, Department of Gastroenterology, Tokyo, Japan;(5)Keio University School of Medicine, Center for Preventive Medicine, Tokyo, Japan;(6)Keio University School of Medicine, Center for Diagnostic and Therapeutic Endoscopy, Tokyo, Japan;(7)National Hospital Organization Saitama Hospital, Department of Gastroenterology, Wako, Japan;(8)Kansai Medical University, Third Department of Internal Medicine- Division of Gastroenterology and Hepatology, Hirakata, Japan;
P419: Outcomes at one year after sequential use of high-dose tofacitinib following infliximab in Acute Severe Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Eqbal, A.(1)*;Hilley, P.(1);Gilmore, R.(1);Li Wai Suen, C.(1);Choy, M.(1,2);De Cruz, P.(1,2);
(1)Austin health, Gastroenterology, Melbourne, Australia;(2)The University of Melbourne- Austin Academic Centre, Medicine, Melbourne, Australia;
P420: Safety & feasibility of targeted mesenteric approaches to ileocolic resection and anastomosis in Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Holubar, S.(1)*;Cohen, B.(2);Uchino, T.(1);Lincango, E.(1);Prien, C.(1);Joseph, A.(2);Achkar, J.P.(2);Gunter, R.(1);Lashner, B.(2);DeLaney, C.(3);Ban, K.(1);Bolshinsky, V.(1);Lipman, J.(1);Liska, D.(1);Philpott, J.(2);Naseer, M.(2);Kanters, A.(1);Braga-Neto, M.(2);Rieder, F.(2);Somovilla, J.(1);Qazi, T.(2);Regueiro, M.(2);Hull, T.(1);Steele, S.(1);
(1)Cleveland Clinic Foundation, Department of Colorectal Surgery, Cleveland, United States;(2)Cleveland Clinic Foundation, Digestive Disease and Surgery Institute, Cleveland, United States;(3)Cleveland Clinic Florida, Department of Colorectal Surgery, Florida, United States;
P421: Real-world effectiveness and safety of vedolizumab induction therapy for Crohn's disease in Poland – a prospective, observational POLONEZ II study considering patient-reported outcomesECCO’23 CopenhagenYear: 2023
Authors: Liebert, A.(1);Kłopocka, M.(1);Cichoż-Lach, H.(2);Michalak, A.(2);Talar-Wojnarowska, R.(3);Domżał-Magrowska, D.(3);Filipiuk, A.(4);Krogulecki, M.(4);Kopertowska-Majchrzak, M.(5);Eder, P.(6);Stawczyk-Eder, K.(6);Waszak, K.(6);Zagórowicz, E.(7,8);Wojciechowski, K.(9,10);Drygała, S.(9)*;
(1)Collegium Medicum in Bydgoszcz- Nicolaus Copernicus University in Toruń, Department of Gastroenterology and Nutritional Disorders, Bydgoszcz, Poland;(2)Medical University of Lublin, Department of Gastroenterology, Lublin, Poland;(3)Medical University of Lodz, Department of Digestive Tract Diseases, Łódź, Poland;(4)Military Institute of Medicine, Department of Gastroenterology, Warsaw, Poland;(5)General Hospital, Department of Internal Diseases, Międzychód, Poland;(6)Poznan University of Medical Sciences- H. Święcicki University Hospital, Department of Gastroenterology- Dietetics- and Internal Diseases, Poznań, Poland;(7)The Maria Sklodowska-Curie National Research Institute of Oncology, Department of Gastroenterology, Warsaw, Poland;(8)The Medical Center of Postgraduate Education, Department of Gastroenterology- Hepatology and Clinical Oncology, Warsaw, Poland;(9)Takeda Pharma sp. z o.o., Medical Affairs, Warsaw, Poland;(10)Independent Public Health Care Center, Department of Internal Diseases, Tarczyn, Poland;
P423: Effect of tofacitinib on colectomy risk in anti TNF-alfa refractory ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Romeo, S.(1)*;Carvalhas Gabrielli, A.M.(1);Ferretti, F.(2);Piazza O Sed, N.(3);Mazzola, A.M.(4);Alicante, S.(1);Berté, R.(1);Scribano, M.L.(5);Buscarini, E.(1);Ricci, C.(4);Caprioli, F.(3,6);Ardizzone, S.(2);Cannatelli, R.(2);
(1)ASST Ospedale Maggiore, Gastroenterology and Digestive Endoscopy Department, Crema, Italy;(2)ASST Fatebenefratelli-Sacco, Gastroenterology Unit - Department of Biomedical and Clinical Sciences- University of Milan, Milan, Italy;(3)Fondazione IRCCS Cà Granda- Ospedale Maggiore Policlinico di Milano, Gastroenterology and Endoscopy Unit, Milan, Italy;(4)Spedali Civili di Brescia, Gastroenterology Unit- Università di Brescia, Brescia, Italy;(5)Villa Stuart Multi-Speciality Clinic, Villa Stuart Multi-Speciality Clinic, Rome, Italy;(6)Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy;
P424: Do antiTNF through levels correlate with joint extraintestinal manifestations (EIM) activity in Inflammatory bowel disease (IBD) patients?ECCO’23 CopenhagenYear: 2023
Authors: Madero Velázquez, L.(1)*;Jovani, V.(2);Andrés, M.(3);Más, P.(4);Aguas, M.(5);Vicens, E.(6);Ojeda, A.(7);Noguera-Pons, J.R.(8);Ranieri, L.(9);Zabana, Y.(10);Pujol, M.(11);Barreiro de Acosta, M.(12);Pérez-Pampin, E.(13);Bernal, L.(14);Belen, O.(14);Moreno, V.(14);García, M.F.(15);Sempere, L.(1);Zapater, P.(16);Gutiérrez Casbas, A.(17);
(1)Hospital General Universitario Dr Balmis de Alicante- ISABIAL, Gastroenterology, Alicante, Spain;(2)Hospital General Universitario Dr Balmis de Alicante- ISABIAL, Reumatology, Alicante, Spain;(3)Hospital General Universitario Dr Balmis de Alicante- ISABIAL- Departamento Medicina Clínica Universidad Miguel Hernández, Reumatology, Alicante, Spain;(4)Hospital General Universitario Dr Balmis de Alicante- ISABIAL, Farmacia hospitalaria, Alicante, Spain;(5)Hospital Policlínico Universitario La Fé, Gastroenterology, Valencia, Spain;(6)Hospital Policlínico Universitario La Fé, Reumatology, Valencia, Spain;(7)Hospital General Universitario Elche, Gastroenterology, Alicante, Spain;(8)Hospital General Universitario de Elche, Reumatology, Alicante, Spain;(9)Hospital Vinalopó, Reumatology, Elche, Spain;(10)Hospital Universitari Mútua Terrassa. CIBERehd, Gastroenterology, Barcelona, Spain;(11)Hospital Universitari Mútua Terrassa, Reumatology, Barcelona, Spain;(12)Hospital Clínico Universitario de Santiago de Compostela. Universidad De Santiago de Compostela, Gastroenterology, Santiago de Compostela, Spain;(13)Hospital Clínico Universitario de Santiago de Compostela, Reumatology, Santiago de Compostela, Spain;(14)Hospital General Universitario Dr Balmis de Alicante, Gastroenterology, Alicante, Spain;(15)Hospital General Universitario de Elche, Gastroenterology, Alicante, Spain;(16)Hospital General Universitario Dr Balmis de Alicante- ISABIAL. Universidad Miguel Hernández- IDiBE-CIBERehd, Clinical Pharmacology, Alicante, Spain;(17)Hospital General Universitario Dr Balmis de Alicante- ISABIAL. CIBERehd, Gastroenterology, Alicante, Spain;
P425: The utility of intestinal ultrasound to inform clinical decision makingECCO’23 CopenhagenYear: 2023
Authors: Yeaman, F.(1)*;Panaccione, R.(1);Ma, C.(1);Lu, C.(1);Seow, C.(1);Kaplan, G.(1);Maracle, B.(1);Novak, K.(1);
(1)University of Calgary- Foothills Medical Centre, Gastroenterology and Hepatology, Calgary, Canada;
P426: Sex and sexuality in IBD - the pediatric gastroenterologists' point of viewECCO’23 CopenhagenYear: 2023
Authors: Anafy, A.(1,2);Cohen, S.(1,2);Matar, M.(3);Shouval, D.S.(2,3);Shamir, R.(2,3);Weintraub, Y.(2,3)*;
(1)Dana-Dwek Children's Hospital- Tel Aviv Sourasky Tel-Aviv Medical Center, Pediatric Gastroenterology Institute, Tel Aviv, Israel;(2)Tel Aviv University, Sackler School of Medicine, Tel Aviv, Israel;(3)Schneider Children's Medical Center of Israel, Institute of Gastroenterology- Nutrition and Liver Diseases, Petach Tikva, Israel;
P427: One Year Follow up of Three Phase IB/IIA Clinical Trials of Ex Vivo Expanded Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulizing Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Lightner, A.(1)*;Otero Pineiro MD , A.(2);Reese, J.(3);Ream, J.(4);Nachand, D.(4);Obi, M.(2);Adams, A.(2);VanDenBossche , A.(2);Dadgar, N.(2);Hull, T.(2);
(1)Cleveland Clinic, Department of Colorectal Surgery, Cleveland, United States;(2)Cleveland Clinic, Colorectal Surgery, Cleveland, United States;(3)Case Western University, Regenerative Medicine, Cleveland, United States;(4)Cleveland Clinic, Radiology, Cleveland, United States;
P428: Pharmacist led clinic in Inflammatory Bowel DiseaseECCO’23 CopenhagenYear: 2023
Authors: Kwok, J.(1)*;Smith, J.(2);Gashau, W.(2);Shuttleworth, E.(2);
(1)Lancashire Teaching Hospitals NHS Foundation Trust, Pharmacy, Preston, United Kingdom;(2)Lancashire Teaching Hospitals NHS Foundation Trust, Gastroenterology, Preston, United Kingdom;
P429: Patient skeletal muscle area and postoperative clinical recurrence in Crohn's disease: a retrospective studyECCO’23 CopenhagenYear: 2023
Authors: Inniss, S.(1,2)*;Simpson, K.(1);Fragkos, K.(1);Wood, C.(1);Smith, A.(2);Rahman, F.(1,2);
(1)University College London Hospitals NHS Foundation Trust, Gastrointestinal Services, London, United Kingdom;(2)University College London, Eastman Dental Institute, London, United Kingdom;
P430: Mesalazine dose modification based on fecal calprotectin levels in ulcerative colitis patients in clinical remissionECCO’23 CopenhagenYear: 2023
Authors: Piñero, G.S.(1,2,3)*;Mañosa , M.(1,3);Cañete, F.(1,3);Calafat, M.(1,3);González, L.(1,3);Ruffinengo, O.(2);Domènech, E.(1,3);
(1)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;(2)Hospital Provincial del Centenario, Gastroenterology, Rosario, Argentina;(3)CiberEHD, Gastroenterology, Madrid, Spain;
P431: A Pan-European Real-World Study of SB5 biosimilar following transition from reference adalimumab: The PROPER study; 48-week analysis of persistenceECCO’23 CopenhagenYear: 2023
Authors: Dignass, A.(1)*;Gisbert, J.P.(2);Bossa, F.(3);Kelly, O.(4);Rahman, M.(5);Lobatón, T.(6);Addison, J.(7);
(1)Agaplesion Markus Hospital- Goethe University, Department of Medicine I, Frankfurt, Germany;(2)Hospital Universitario de La Princesa- Instituto de Investigación Sanitaria Princesa IIS-Princesa- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD- Universidad Autónoma de Madrid UAM, Gastroenterology Unit, Madrid, Spain;(3)Fondazione Casa Sollievo della Sofferenza – IRCCS - San Giovanni Rotondo, Division of Gastroenterology, Puglia, Italy;(4)Connolly Hospital, Department of Gastroenterology, Dublin, Ireland;(5)Surrey and Sussex Healthcare NHS Trust, Department of Gastroenterology, Surrey, United Kingdom;(6)Ghent University Hospital, Department of Internal Medicine and Pediatrics- Department of Gastroenterology, Ghent, Belgium;(7)Biogen Idec Ltd, Clinical Research, Maidenhead, United Kingdom;
P432: Patient satisfaction and patient costs associated with telephone clinic appointments in Inflammatory Bowel Disease (IBD) following the pandemicECCO’23 CopenhagenYear: 2023
Authors: Matini, L.(1)*;Stokes, E.A.(2);Parra Mujica, F.(3);Kormilitzin, A.(4);Kantschuster, R.(1);Punj Sharda, A.(1);Dunbar, G.(1);Song, K.(1);White, L.(1);Travis, S.P.L.(5);Walsh, A.(1);
(1)University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom;(2)University of Oxford. NIHR Oxford Biomedical Research Centre- UK., Health Economics Research Centre, Oxford, United Kingdom;(3)University of Oxford, Health Economics Research Centre, Oxford, United Kingdom;(4)University of Oxford, Mathematical Insitute, Oxford, United Kingdom;(5)University of Oxford, Kennedy Institute, Oxford, United Kingdom;
P433: Efficacy of risankizumab by baseline clinical, biochemical, and endoscopic disease severity in moderately to severely active Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Panaccione, R.(1)*;D'Haens, G.(2);Seenan, J.P.(3);Caprioli, F.(4,5);Siegel, C.(6);Nakamura, M.(7);Wei, S.C.(8);Kligys, K.(9);Zhang, Y.(9);Zambrano, J.(9);Song, A.P.(9);Ferrante, M.(10);
(1)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;(2)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands Antilles;(3)Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom;(4)Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy;(5)Fondazione IRCCS Cà Granda- Ospedale Maggiore Policlinico di Milano, Gastroenterology and Endoscopy Unit, Milan, Italy;(6)Dartmouth-Hitchcock Medical Center, Inflammatory Bowel Disease Center- Section of Gastroenterology and Hepatology, Lebanon, United States;(7)Nagoya University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Nagoya, Japan;(8)National Taiwan University Hospital and College of Medicine, Department of Internal Medicine, Taipei, Taiwan;(9)AbbVie Inc., Research and Development, North Chicago, United States;(10)KU Leuven, Department of Gastroenterology and Hepatology- University Hospitals Leuven, Leuven, Belgium;
P434: Upadacitinib improved fatigue and health-related quality of life in patients with moderately to severely active Crohn's disease: Results from induction and maintenance phase 3 trialsECCO’23 CopenhagenYear: 2023
Authors: Ghosh, S.(1)*;Feagan, B.(2);Parra, R.S.(3);Lopes, S.(4);Steinlauf, A.(5);Kakuta, Y.(6);Joshi, N.(7);Lee, W.J.(7);Remple, V.(7);Lacerda, A.P.(7);Zhou, Q.(7);Xuan, S.(7);Louis, E.(8);
(1)University College Cork, College of Medicine and Health, Cork, Ireland;(2)Western University, n/a, London, Canada;(3)University of São Paulo, Ribeirão Preto Medical School, São Paulo, Brazil;(4)Centro Hospitalar e Universitário São João, n/a, Porto, Portugal;(5)Mount Sinai Hospital, IBD Clincal Center, New York, United States;(6)Tohoku University Graduate School of Medicine, Division of Gastroenterology, Sendai, Japan;(7)AbbVie Inc., n/a, Chicago, United States;(8)Centre Hospitalier Universitaire de Liège, Department of Gastroenterology, Liège, Belgium;
P435: Real-world comparison of effectiveness between ustekinumab and a second anti-TNF agent in patients with symptomatic stenosing Crohn's disease after failure of a first anti-TNF agent: results of the USTEKNOSIS studyECCO’23 CopenhagenYear: 2023
Authors: Buisson, A.(1)*;Jammet, A.(1);Pereira, B.(2);Fumery, M.(3);
(1)CHU Clermont-Ferrand, IBD Unit, Clermont-Ferrand, France;(2)CHU Clermont-Ferrand, Biostatistics Unit, Clermont-Ferrand, France;(3)CHU Amiens, IBD Unit, Amiens, France;
P436: Efficacy and safety of intravenous ustekinumab re-induction therapy in Crohn's disease patients with secondary loss of response to ustekinumab maintenance therapy: Week 16 results from the POWER trialECCO’23 CopenhagenYear: 2023
Authors: Schreiber, S.W.(1)*;Lee, S.(2);van der Woude , C.J.(3);Marín-Jiménez , I.(4);Wolf, D.(5);Schnoy, E.(6);Salzberg , B.(7);Busse , C.(8);Nazar, M.(9);Langholff, W.(10);Borghorst, S.(11);Gasink, C.(8);Baker, T.(12);Godwin, B.(8);Feagan, B.(13);
(1)Christian-Albrechts-University and University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(2)University of Washington, Division of Gastroenterology, Seattle, United States;(3)Erasmus University Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands;(4)Hospital Universitario Gregorio Marañón- IiSGM, Gastroenterology Unit, Madrid, Spain;(5)Atlanta Gastroenterology Associates, Center for Crohn's Disease & Ulcerative Colitis, Atlanta, United States;(6)University Hospital of Augsburg, Internal Medicine III- Gastroenterology, Augsburg, Germany;(7)IBD Center of Atlanta, Atlanta Gastroenterology Specialists PC, Atlanta, United States;(8)Janssen Scientific Affairs- LLC, Gastroenterology, Horsham, United States;(9)Janssen-Cilag Polska Sp. z.o.o., Gastroenterology, Warsaw, Poland;(10)Janssen Research & Development- LLC, Biostatistics, Spring House, United States;(11)Janssen-Cilag GMBH, Health Economics/Market Access/Reimbursement, Neuss, Germany;(12)Janssen Research & Development- LLC, Immunology, Spring House, United States;(13)University of Western Ontario, Division of Gastroenterology- Department of Medicine, London, Canada;POWER Investigators
P437: Early therapeutic drug monitoring of Adalimumab, but not HLADQ*A1 determination, predicts inflammatory bowel disease outcome .ECCO’23 CopenhagenYear: 2023
Authors: Carrillo Palau, M.(1)*;Alonso-Abreu, I.(1);Morant, A.(1);Vera, B.(1);Vela , M.(2);Ramos, L.(1);Franco, A.(3);Reygosa, C.(1);Barrios, Y.(3);Medina Chico, J.S.(1);Globio, V.(4);Hernández-Perez, A.(1);Jiménez, A.(5);Hernández-Guerra, M.(1);
(1)Hospital Universitario De Canarias, Gastroenterology, Santa Cruz De Tenerife, Spain;(2)Hospital Universitario Nuestra Señora de La Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain;(3)Hospital Universitario de Canarias, Immunology, Santa Cruz de Tenerife, Spain;(4)La Laguna University, Medicine Faculty, Santa Cruz de Tenerife, Spain;(5)Hospital Universitario de Canarias, Research, Santa Cruz de Tenerife, Spain;
